<DOC>
	<DOCNO>NCT02299635</DOCNO>
	<brief_summary>This study design evaluate preliminary anti-tumor activity tolerability PF-03084014 administer single agent treatment patient advanced triple receptor-negative breast cancer ( mTNBC ) harbor genomic alteration Notch receptor ( NA+ ) , small subset mTNBC patient whose tumor test negative genomic alteration Notch receptor ( NA- )</brief_summary>
	<brief_title>A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Histological cytological diagnosis triple negative breast cancer ( TNBC ) evidence ) metastatic b ) locally recurrent advanced disease amenable resection radiotherapy curative intent . Availability original diagnostic tumor tissue recent metastatic tumor biopsy ( archival biopsy de novo biopsy ) peripheral blood sample Notch receptor genomic profile Known brain metastasis . Prior treatment gamma secretase inhibitor Notch signal inhibitor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PF-03084014</keyword>
	<keyword>Notch Alterations</keyword>
</DOC>